Status:
COMPLETED
Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age
Lead Sponsor:
Pfizer
Conditions:
Fetal Growth Retardation
Eligibility:
All Genders
4-9 years
Phase:
PHASE3
Brief Summary
To estimate the percentage of children with serum IGF-1 \> 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after...
Eligibility Criteria
Inclusion
- Chronological age between 4 and 9 years for a boy and 4 and 7 years for a girl.
- Measured Height \< -2.5 Standard Deviation
Exclusion
- Pubertal signs ie: testis volume \> or = 4 ml in boys and breast stage \> or = B2 (Tanner)
- Serious chronic disease (diabetes, renal insufficiency, heart failure, hepatic insufficiency, neoplasia)
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00174252
Start Date
February 1 2005
End Date
April 1 2009
Last Update
June 15 2010
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Amiens, France, 80030
2
Pfizer Investigational Site
Angers, France, 49000
3
Pfizer Investigational Site
Besançon, France, 25030
4
Pfizer Investigational Site
Bordeaux, France, 33000